Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MoonLake Immunotherapeutics

MLTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$16.47

▼ -0.18%

Market Cap $1.40B · Vol 347.74K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.40B

Small Cap

Div Yield

N/A

EPS Growth

-3.43%

YoY

RSI (14)

29.68

Momentum

Beta

0.96

vs Market

52W High

$62.73

73.74% below

52W Low

$5.96

176.57% above

Volume

347.74K

Avg 351.31K

P/B

3.09

Price-to-book

ROE

-60.58%

Return on equity

Free Float

91.89%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, MoonLake Immunotherapeutics (MLTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MLTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.80%

-15.63%

-10.44%

+4.44%

YTD

+24.96%

-69.99%

-70.74%

+65.69%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-230,321,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-60.58%
ROA · ROIC	-50.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.09
P/FCF	N/A
EPS Growth	-3.43%
Outstanding Shares	85.11M

Technical Indicators

50-Day SMA	$18.87
200-Day SMA	$16.56
RSI (14)	29.68
Beta	0.96
52-Week High	$62.73
52-Week Low	$5.96

Volume Today	347.74K
Avg Daily Volume (30D)	351.31K
Relative Volume	0.99x
Volatility (10D)	55.43
Volatility (30D)	55.76
Free Float	91.89%

Analyst Consensus

BUY

Current Price $16.47

Mean Target $31.50

52W Low$5.96 52W High$62.73

Current

Target

$5.96 $62.73

Current Analyst target

+91.26% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00XQZQVP7

ISINKY61559X1045

CountrySwitzerland

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.